Consistently, in a study from the European MCL Network with patients treated with ara-C containing regimens, cases with low SOX11 expression (<10% of SOX11+ tumor cells) had a shorter time-to-treatment failure and shorter overall survival than SOX11+ cases.8 This evidence concerns the gene SOX11 and mantle cell lymphoma.